WTA
IOVA icon

Washington Trust Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Washington Trust Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-197
Closed -$1.26K – 785
2022
Q4 		$1.26K Hold
197
– – ﹤0.01% 754
2022
Q3 		$2K Hold
197
– – ﹤0.01% 855
2022
Q2 		$2K Hold
197
– – ﹤0.01% 878
2022
Q1 		$3K Hold
197
– – ﹤0.01% 895
2021
Q4 		$4K Buy
+197
New +$4.34K ﹤0.01% 885

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Washington Trust Advisors's IOVA Position: Q1 2023 in Review

Washington Trust Advisors sold out of Iovance Biotherapeutics (IOVA) in Q1 2023, closing a stake of 197 shares — an estimated $1.26K sold.

Washington Trust Advisors first reported a position in IOVA in Q4 2021 and held it in 5 quarters. The position peaked at $4K in Q4 2021. 228 funds tracked by Wall St. Rank hold IOVA as of Q1 2023.

  • Washington Trust Advisors reported no remaining Iovance Biotherapeutics position as of Q1 2023 after selling out during the quarter.
  • Washington Trust Advisors sold 197 Iovance Biotherapeutics shares in Q1 2023, an estimated $1.26K.
  • Washington Trust Advisors first reported a position in Iovance Biotherapeutics in Q4 2021 and held it in 5 quarters.
  • Washington Trust Advisors's Iovance Biotherapeutics position peaked at $4K in Q4 2021.
  • 228 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2023.

Based on Washington Trust Advisors's 13F filing for Q1 2023, filed 4 May 2023.